Ai Takemoto

877 total citations
15 papers, 592 citations indexed

About

Ai Takemoto is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ai Takemoto has authored 15 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ai Takemoto's work include Lymphatic System and Diseases (8 papers), Lymphatic Disorders and Treatments (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). Ai Takemoto is often cited by papers focused on Lymphatic System and Diseases (8 papers), Lymphatic Disorders and Treatments (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). Ai Takemoto collaborates with scholars based in Japan, United States and Sweden. Ai Takemoto's co-authors include Naoya Fujita, Satoshi Takagi, Miho Takami, Kenichi Miyata, Makoto Nishio, Shigeo Sato, Sakae Okumura, Tomoko Oh‐hara, Julie Rayes and Tomoyuki Miyashita and has published in prestigious journals such as Oncogene, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Ai Takemoto

13 papers receiving 587 citations

Peers

Ai Takemoto
Miho Takami Japan
Monika Haemmerle Germany
Satoshi Takagi Japan
Caroline Wallace United States
Brett H. Herzog United States
Beth A. Markens United States
Elizabeth Masse United States
Carla Castanaro United States
Giovanni Roveroni Italy
Carolina Zandueta Spain
Miho Takami Japan
Ai Takemoto
Citations per year, relative to Ai Takemoto Ai Takemoto (= 1×) peers Miho Takami

Countries citing papers authored by Ai Takemoto

Since Specialization
Citations

This map shows the geographic impact of Ai Takemoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ai Takemoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ai Takemoto more than expected).

Fields of papers citing papers by Ai Takemoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ai Takemoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ai Takemoto. The network helps show where Ai Takemoto may publish in the future.

Co-authorship network of co-authors of Ai Takemoto

This figure shows the co-authorship network connecting the top 25 collaborators of Ai Takemoto. A scholar is included among the top collaborators of Ai Takemoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ai Takemoto. Ai Takemoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Suzuki, Mai, Ken Uchibori, Tomoko Oh‐hara, et al.. (2024). A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer. npj Precision Oncology. 8(1). 46–46. 5 indexed citations
2.
Uchibori, Ken, Ai Takemoto, Sumie Koike, et al.. (2024). MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer. Cancer Letters. 604. 217220–217220.
3.
Takagi, Satoshi, Sumie Koike, Miho Takami, et al.. (2024). Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma. Oncogene. 44(12). 794–804.
4.
Shimizu, Yuki, Ai Takemoto, Tomoko Oh‐hara, et al.. (2023). MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. JCI Insight. 8(24). 5 indexed citations
5.
Takemoto, Ai, Satoshi Takagi, Nobuhiko Gyobu, et al.. (2022). Targeting Podoplanin for the Treatment of Osteosarcoma. Clinical Cancer Research. 28(12). 2633–2645. 19 indexed citations
6.
Sakata, Seiji, Bo Gong, Yosuke Seto, et al.. (2021). Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight. 7(1). 37 indexed citations
7.
Takagi, Satoshi, Sumie Koike, Ai Takemoto, et al.. (2021). Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis. Oncogene. 40(36). 5548–5558. 33 indexed citations
8.
Takemoto, Ai, et al.. (2021). Novel knock‐in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin–targeting agents. Cancer Science. 112(6). 2299–2313. 3 indexed citations
9.
Takemoto, Ai, et al.. (2018). A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis). Oncotarget. 9(70). 33322–33336. 7 indexed citations
10.
Krishnan, Harini, Julie Rayes, Tomoyuki Miyashita, et al.. (2018). Podoplanin: An emerging cancer biomarker and therapeutic target. Cancer Science. 109(5). 1292–1299. 135 indexed citations
11.
Takemoto, Ai, Satoshi Takagi, Miho Takami, et al.. (2017). A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis. Scientific Reports. 7(1). 42186–42186. 98 indexed citations
12.
Miyata, Kenichi, Ai Takemoto, Sakae Okumura, Makoto Nishio, & Naoya Fujita. (2017). Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation. Scientific Reports. 7(1). 4059–4059. 38 indexed citations
13.
Takemoto, Ai, Kenichi Miyata, & Naoya Fujita. (2017). Platelet-activating factor podoplanin: from discovery to drug development. Cancer and Metastasis Reviews. 36(2). 225–234. 69 indexed citations
14.
Takemoto, Ai, et al.. (2015). Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget. 7(4). 3934–3946. 69 indexed citations
15.
Takagi, Satoshi, Ai Takemoto, Miho Takami, Tomoko Oh‐hara, & Naoya Fujita. (2014). Platelets promote osteosarcoma cell growth through activation of the platelet‐derived growth factor receptor‐Akt signaling axis. Cancer Science. 105(8). 983–988. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miho Takami Breakdown of academic impact, for papers by Monika Haemmerle Breakdown of academic impact, for papers by Satoshi Takagi Breakdown of academic impact, for papers by Caroline Wallace Breakdown of academic impact, for papers by Brett H. Herzog Breakdown of academic impact, for papers by Beth A. Markens Breakdown of academic impact, for papers by Elizabeth Masse Breakdown of academic impact, for papers by Carla Castanaro Breakdown of academic impact, for papers by Giovanni Roveroni Breakdown of academic impact, for papers by Carolina Zandueta
Rankless by CCL
2026